secwatch.observer — SEC 8-K summary
======================================

Issuer:     LivaNova PLC (LIVN)
CIK:        0001639691
Form:       8-K
Filed at:   2024-05-01T23:59:59+00:00
Accession:  0001639691-24-000054
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LivaNova Q1 revenue $294.9M (+12% YoY); raises FY2024 guidance; OSPREY study positive
--------------------------------------------------------------------------------

- Q1 revenue $294.9M, up 12.0% reported, 12.4% constant-currency YoY; adjusted EPS $0.73 vs GAAP loss $0.78.
- Cardiopulmonary and Neuromodulation each grew double-digit; ACS wind down on track for end-2024.
- Raised full-year 2024 revenue and adjusted diluted EPS guidance (exact figures not in excerpt).
- Positive predictive outcome in OSPREY obstructive sleep apnea study; enrollment completed.
- Closed $345M 2.50% convertible notes due 2029; repurchased $230M exchangeable notes due 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1639691/000163969124000054/0001639691-24-000054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1639691/000163969124000054/livn-20240501.htm
  HTML page:      https://secwatch.observer/filing/0001639691-24-000054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer